Question	Answer	Written Answer
Could you also put the event page link in the chat?	Answered in Q&A Pod	2023 FDA Broad Agency Announcement Day https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023
Are co-principal investigators allowed on the application?	Answered Live	
Can you give some insight on the amount of money available for awards through this BAA? What is the average size of an award?	Answered Live	
What is the data sharing or publication requirements?	Answered Live	
Can you fund all phases of clinical trials?	Answered in Q&A Pod	Clinical trials to support regulatory research and development may be funded via the BAA Program. Please refer to Federal Acquisition Regulations (FAR) definitions for basic research (See FAR 2.101(b)(2)), applied research (See FAR 35.001) and development (See FAR 35.001). https://www.acquisition.gov/far/35.001
How many applications are anticipated for this round of funding?	Answered Live	
Where can we find the codes and explanation/definition of the FDA Primary Research Areas? Such as I.C.3.a. Secondary Research Area: I.F.4.b., Primary Research Area (i.e., II.B.7.e)	Answered in Q&A Pod	Please review Dr. Kinnera Chada's presentation
Looking for information on GDUFA initiatives on Topical products and characterization-based approach	Answered in Q&A Pod	This was covered in the first presentation, thank you for your question!
Is there a limit of applications per institution?	Answered in Q&A Pod	There is no limit on applications per institution
For this proposal, can we assign co-PIs from 2 different institutions?	Answered Live	
Will proposals that address these items be sent to the Generics division for review or does it go to a central review team?	Answered Live	
Why have we not heard the feedback from the 2023 FDA BAA concept paper submission?	Answered in Q&A Pod	To our knowledge all feedback and rejection letters have been sent out. Please reach out to me directly at Ian.Weiss@fda.hhs.gov and we will get you the information you need.
I am a Univ. faculty in AI and Machine Learning. To apply for FDA grant, do I have to partner with a MD or someone within FDA?	Answered Live	
Is developing IVPT skin penetration robustness an area of interest	Answered Live	
Are you looking for a proposal to cover multiple items you have listed (for example 1-3 under nitrosamines) or are you looking for a proposal to cover a single item	Answered Live	

Question	Answer	Written Answer
For clarification, based on the topic area	Answered	
overview, the goal of this BAA for the FDA is to	Live	
obtain new ways of testing and validating		
products that come through the FDA for		
clearance/approval, not for industry to share		
new devices or therapeutics?		
Are proposals for developing Methodology to	Answered	
improve clinical trial diversity of interest?	Live	
Please provide the link to the detailed list of	Answered	All details on research areas can be found in the
fields that we can apply in, mentioned by the	in Q&A Pod	BAA announcement on SAM.gov:
Speaker		https://sam.gov/opp/b4906ee0af3c48de9a793049
		a63695e5/view
Will other CDER offices present their priorities		No, only the Centers and Offices listed on the
(OND?)		agenda will be presenting the priorities. See Part I
		of the solicitation on SAM.gov for details.
Recently, CRCG posted an opportunity on TDS	Answered	
patch adhesion. Would areas around	Live	
adhesion assessment, still be encouraged in		
the BAA process.		
Can smartphone apps that track habits such as	Answered	Please refer to the FY24 BAA solicitation for scope
nicotine habits with data recording/AI/ML	in Q&A Pod	under Tobacco Products.
support etc. be of some interest to current BAA?		https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8
Just curious at this point.		314343cb/view
Based on the feedback received last year, where	Answered	
our proposal was recognized as scientifically	Live	
sound but had concerns about industry adoption		
and regulatory implementation, can we resubmit an enhanced proposal this year addressing these		
concerns? Additionally, can we reference the		
previous feedback in our revised concept paper?		
What is the website that all of these will be	Answered	
posted to?	Live	
Can interchangeable processing of the same	Answered	
product be considered under this program?	Live	
website for the recording and slides	Answered	Recording of the full event (including closed
· ·	in Q&A Pod	captioning and an audio transcript), presentation
		slides, and responses to all questions will be
		posted on the event page.
Given that this meeting is happening only 10	Answered	The BAA Announcement was posted on October
days prior the deadline for early concept	in Q&A Pod	2, 2023, and the FDA feels 6 weeks for an
submission (Nov. 6th), can that deadline be		optional 3-page paper is a sufficient amount of
extended by a week?		time. As such, no extensions will be granted.
what is the event page website?	Answered	https://www.fda.gov/science-research/2023-fda-
	in Q&A Pod	broad-agency-announcement-day-10252023
Will you be covering Chare 3 and specifically	Answered	Only the funding priorities listed by FDA
Antimicrobial Resistance in this webinar?	in Q&A Pod	Programs on the agenda will be presented.
		https://www.fda.gov/science-research/2023-fda-
		broad-agency-announcement-day-agenda

What are the priorities in terms disease areas for the CDRH? Does the Concept Paper 3-page limit include the cover page? Answered will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? Answered will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? Answered will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? Answered will a web construing of a manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing support improvements to gene therapy manufacturing support improvements to gene therapy manufacturing? Answered Live Will CDRH support improvements to gene therapy manufacturing is got interest as well? Will CDRH support improvements to gene therapy manufacturing is got interest as well? Will CDRH support improvements to gene therapy manufacturing support improvements to gene therapy manufacturing? Answered Live Answered Live Answered Live See drug and cross-cutting sections on advanced manufacturing or the solicitation. There are no CDRB specific topics related to MCM manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness Addressed live by the presenter in Q&A Pod live Answered Liv	Question	Answer	Written Answer
the CDRR? Does the Concept Paper 3-page limit include the cover page? Will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? Will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? For the MCM, are there modalities that are of priority? i.e., microbiome versus vaccine will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDR1 support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? Value Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipelines that support data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	_ ·		
Does the Concept Paper 3-page limit include the cover page? Also, will provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? For the MCM, are there modalities that are of priority? i.e., microbiome versus vaccine will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing; but one were you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipelines that support data analysis for FDA reviewers? Pipelenies like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Mowered and province of the proposal of the province of the concept paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	·		
cover page? Will FDA provide a link to this recorded session? Also, will it be posted on the FDA website or emailed to registered attendees? Recording of the full event (including closed in Q&A Pod april to PDA BAA event page: https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023 For the MCM, are there modalities that are of priority? i.e., microbiome versus vaccine will advance manufacturing guality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing. Answered Live Answered Li			Yes, the 3-page limit for Concept Paper incudes
Answered contents or a consortium of multiple? Answered therapy manufacturing? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? Answered to have you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? (a) Mill contents regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for Women's Health)? Under immuno-oncology are you interested in MCM annumon-oncology are you interested in McM in Q&A pod different centers of Communo-oncology are you interested in McM cancer and Women's Health)? Answered Live Answered Live Answered Live Answered Live Answered Live Answered Live See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to Shortages, and emergency preparedness Addressed live by the presenter in Q&A pod in QAA pod			
Also, will it be posted on the FDA website or emailed to registered attendees? In Q&A Pod captioning and an audio transcript), presentation slides, responses to polis, and answers to all questions (received via email to FDABAA mailbox and live) will be posted on FDA BAA event page: https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023 For the MCM, are there modalities that are of priority? i.e., microbiome versus vaccine will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? 'Puluie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for PDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health) as entries for Demographics and Population Answered Live Live See drug and cross-cutting sections on advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness Addressed live by the presenter in		Answered	·
questions (received via email to FDABAA mailbox and live) will be posted on FDA BAA event page: https://www.fda.gov/science-research/2023-fda-broad-agency-announcement-day-10252023 For the MCM, are there modalities that are of priority? i.e., microbiome versus vaccine will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? Answered Live See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? ("Quille Schniders: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipeline development proposals" that will facilitate regulatory data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Live Damographics and Population Answered Live Damographics and Population Answered Live Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	Also, will it be posted on the FDA website or	in Q&A Pod	
of priority? i.e., microbiome versus vaccine will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness Addressed live by the presenter in Q&A Pod live Answered Live Addressed live by the presenter in Q&A Pod Live Answered Live Addressed live by the presenter in Q&A Pod Live Answered Addressed live by the presenter in Q&A Pod Live Answered Live An			questions (received via email to FDABAA mailbox and live) will be posted on FDA BAA event page: https://www.fda.gov/science-research/2023-fda-
will advance manufacturing quality focus on devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? Answered Live See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? Pululie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in		Answered	
devices or also pharmaceutical manufacturing is of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Live Answered Live Answered Live Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population			
of interest as well? Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered			
Will CDRH support improvements to gene therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? Can you darify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered		Live	
therapy manufacturing/supply chain specific proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hellol What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Live Answered Live Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population		Anguerad	
proposals? Do you prefer to work with a single academic center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Live See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness Answered Live Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	,, ,		
Center or a consortium of multiple? Can you clarify if CDER is also interested in MCM manufacturing? See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Answered Live See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Under immuno-oncology are you interested in	proposals?	Live	
See drug and cross-cutting sections on advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness. How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered Live Cancer and Women's Health as entries for Demographics and Population			
advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to shortages, and emergency preparedness How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Answered Live Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	•	Live	
How are you addressing where there seems to be overlap in subjects between this BAA and other NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population			advanced manufacturing of the solicitation. There are no CDER specific topics related to MCM manufacturing, but we see a lot of advanced manufacturing proposals utilize candidates or model systems related to
NIH announcements that uses very similar text? '@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Live Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	How are you addressing where there seems to be	Answered	
'@Julie Schneider: Significant part of Oncology CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered Answered Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population	_	in Q&A Pod	
CGTP products evaluation and long-term monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Live For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered Under immuno-oncology are you interested in	•		
monitoring relies heavily on Bioinformatics pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population			
pipelines that support data analysis. Does OCE support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population		Live	
support "purely bioinformatics pipeline development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered	· · · · · · · · · · · · · · · · · · ·		
development proposals" that will facilitate regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered	• •		
regulatory data analysis for FDA reviewers? Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered	•• • •		
Pipelines like Off-target, on-target, viral integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered			
integration, AAV consistency of manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered			
manufacturing, etc. Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Answered For the Concept Paper, provide Persons with Cancer and Women's Health as entries for Demographics and Population Answered	·		
Hello! What if I have a proposal that could be relevant for two different centers (e.g., OCE and Office of Women's Health)? Answered Live Cancer and Women's Health as entries for Demographics and Population Answered Answered Answered Answered Answered	,		
relevant for two different centers (e.g., OCE and Office of Women's Health)? Under immuno-oncology are you interested in Live Cancer and Women's Health as entries for Demographics and Population Answered		Answered	For the Concept Paper, provide Persons with
Under immuno-oncology are you interested in Answered	relevant for two different centers (e.g., OCE and		Cancer and Women's Health as entries for
	<u>-</u>	Answered	
as colitis?	therapeutics that can alleviate side effects such	Live	

Question	Answer	Written Answer
Can multiple investigators from different		Yes, this is acceptable to the Govt. However,
institutions be on the same proposal?		please keep the 51% rule in mind with regards to subcontracting, as well as provide a primary POC.
@Julie.Schneider@fda.hhs.gov, there seems to	Answered	
be similar language between some BAA topics	Live	
and NIH solicitations, should this be		
complementary to those?		
Does non-radioactive reagents for LN mapping	Answered	
area of interest for OCE?	Live	
Does your center have interest in technologies	Answered	
that can aid in patient health evaluation under	Live	
telehealth?		Funding has not been determined Diseases
I thought I asked this already but don't see it		Funding has not been determined. Please see
here. This applies to all topic areas. I was wondering what the available funding is for this		Prior Year Award postings for historical data.
FY24 BAA and what the typical size award is		
through this funding mechanism. It really helps to		
know this as it impacts the size project/scope a		
company can propose.		
Do you require BSL3 strains for MCM research, or	Answered	
is use of BSL2 surrogate strains acceptable, if it	Live	
can show proof of concept?		
Would on demand GCSF mfg. be of interest?	Answered	
	Live	
Do you support clinical trials of MCM's?	Answered	
	Live	
Does Covid-19 is still an	Answered	
interesting topic for FDA?	Live	
Dose you center have interest in technology for	Answered	
distributed manufacturing of vaccine products?	Live	
What types of supply chain resilience topics are	Answered	
of highest priority?	Live	
Is 3D printing of countermeasure as a method for on-demand and decentralized	Answered	
countermeasure production method, of an	Live	
Would you consider proposals for development	Answered	
of novel NGS-based diagnostics. If not, can you	Live	
give an example of the types of tools you are	LIVC	
looking for that would enhance NGS-based		
diagnostics that may be applicable?		
How do you see Large Language Models	Answered	
impacting proposals	Live	
Are you interested on modelling of advanced	Answered	OCET Advanced Manufacturing Program would be
manufacturing?	Live	interested in digital twins and other computational
		/ AI models of advanced manufacturing processes.
		Especially interested in models that help optimize
		processes, perform real-time or adaptive control,
		and ones for development of new processes.

Question	Answer	Written Answer
Are novel surrogate endpoints to advance MCM's	Answered	This is not a primary focus of the OCET Advanced
of interest?	Live	Manufacturing Program.
How do submit a concept paper	Answered in Q&A Pod	Please see Section 2: Stage 1 Concept Paper and Full Proposal of Part III: Proposal Preparation and Submission of FY24 BAA Solicitation. https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8 314343cb/view
How can we get information from the Advance manufacturing group?	Answered Live	Please contact James.Coburn@fda.hhs.gov or Kirstie.Snodderly@fda.hhs.gov
Which type of advanced manufacturing process is of FDA interest? Solid dosages or liquid dosages or both?	Answered Live	FDA (broadly speaking) is interested in many types of advanced manufacturing, especially those that are within 1-5 years of being implemented by industry. Each Center focuses on a specific set of those technologies, and each will define "advanced" manufacturing slightly differently. OCET concentrates on advanced manufacturing technologies and processes that can be applied to more than one type of product (i.e. solid and liquid dosage forms, vaccines and antibodies, etc). This aligns with our role of bringing topics that are relevant to multiple Centers.
Will the answers to the manufacturing questions be posted after you follow up with your colleagues?	Answered Live	Yes, answers will be posted
In the scope of real-world evidence, are there any specific areas of research that have more need than others?	Answered Live	
Related to the concept paper, is it possible to get an example of a good one?	Answered in Q&A Pod	Please see attachment 4 of FY24 BAA solicitation for a template for the Concept Paper. https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8 314343cb/view
Would evaluation of the mitigation and response efforts have implemented during COVID and providing an evaluation and next steps on human and animal food supply chains. be of interest?	Answered Live	Evaluation of the mitigation and response efforts implemented during COVID and providing an evaluation and next steps on human and animal food supply chains are currently not a priority. We could be convinced that this would be of interest but only if the "next steps" part is the majority of the report and the steps are grounded in a lot of policy analysis, with all the pitfalls, challenges, and nuances that would entail.
Will tech that shows lower cost be of interest?	Answered Live	Really like to see the research lower costs AND/OR (Help bring manufacturing back to the U.S. OR Move the ecosystem towards biomanufacturing and away from petrochemicals) - Parentheses for Boolean grouping purposes.
Which center focuses on substance use and misuse topics, especially around medication for opioid use disorder		CDER

Question	Answer	Written Answer
Is the length of the concept paper 1 Cover Page +	Answered	- A biomanufacturing method for
3 Pages of Concept paper or 1 Cover Page + 2	in Q&A Pod	polypropylene precursors that make them out
Pages of Concept Paper?		from ecoli instead of oil.
Under One Health approaches 1. Crosscutting b.	Answered	- Automation / biomanufacturing that lowers
Develop methods to assess the impact of	Live	the cost of making the key starting materials for
contaminants on human, animal, and		certain active pharmaceutical ingredient (API),
environmental health, including the distribution		which makes it easier from domestic producers to
and fate of contaminants in natural ecosystems,		compete.
and develop tools to better assess risk and to		
predict how sources for human and animal		
exposures may affect the safety of medical		
products and human and animal food. If this		
looking for a monitoring tool, or would a review		
of biological contaminants distribution and fate		
in the environment be of interest?		
What if the proposal address FDA's regulatory	Answered	
needs as well as CDCs mission. Can a proposal be	Live	
co-submitted/co-funded by two agencies through		
some kind of interagency agreement?	A	
Intersex?	Answered	
Mould broost concar diagnostics he of interest	Live Answered	Project concor diagnostics could not ontially be of
Would breast cancer diagnostics be of interest	Live	Breast cancer diagnostics could potentially be of interest; we would need to see the concept paper
	Live	to fully evaluate.
What is a SAM registration?	Answered	https://sam.gov/content/home
Apologies for not knowing :)	in Q&A Pod	nacps.//sum.gov/content/nome
Are you interested in social media data	Answered	Please see Part I of the solicitation for details.
analysis for monitoring tobacco product	Live	
marketing and user behavior changes? Thanks!		
What was the reason of asking for full proposals	Answered	
in February? FDA may get many more full	Live	
proposals than before without a pre-screening.		
Sorry, interrupted message: are concept	Answered	The optional early concept papers that are due in
papers due in November acting similarly as the	in Q&A Pod	November are 1. optional and 2. more like Quad
white papers were previously?		Charts that will reviewed for high-level
Are the approval, utility, and value of the	Answered	OWH funds research that advances FDA regulatory
technologies indicated for the pregnant women	Live	decision-making, advances the understanding of
to determine congenital malformations within		sex differences, and investigates conditions unique
the scope of Women's health? other FDA center?		to women.
or not covered by FDA in general since the		
laboratory tests are outside the scope of the		
FDA's authority?		
Does the three (3) page limit for the concept	Answered	
paper (specified on page 70 of the Broad Agency	Live	
Announcement) include the Concept Paper Cover		
Page?	A marria #= -!	
Do international submitters need a SAM?	Answered	
	Live	

Question	Answer	Written Answer
Table 3: Overview of BAA Application Process on	Answered	
page 96 of the Broad Agency Announcement	Live	
indicates that the FDA will notify submitters of		
the Optional Early Concept Paper of the interest		
or lack of interest for full proposal submission.		
Does the FDA have a target date or date range		
in mind for sending these notifications out?		
Thanks, this means we most likely most will be		No answer, this is a comment.
sent as full proposal in February		
We still have a BAA submission from 2023 that		This is a business decision. However, you are
has not been awarded or rejected. Should we re-		allowed to re-submit.
submit the topic under the 2024 program, or wait		
for the 2023 program to complete?		
If the US government shuts down, will it affect	Answered	
your timelines?	Live	
the FY24 BAA "solicitation for scope under	Answered	We did not find any links that are not operational.
tobacco products" website link is not working.	in Q&A Pod	Please send an email to FDABAA@fda.hhs.gov an
		email with the website link that is not working.
I thought the concept paper was optional. Can	Answered	
you clarify this for us? Thanks	Live	
Is there a limit for requested yearly funding?		No, but historically, most BAA awards are 1 million
		per year or less.
When can we expect to hear back on a		yes, basic feedback and a recommendation will be
recommendation on the optional early concept		given by December 15th, 2023.
paper?		
When is the concept paper due date?	Answered	
	Live	
How much feedback will be provided about	Answered	
decisions for concept paper rejection or ways to	Live	
better focus proposals for future submissions?		
when will the outcomes be communicated	Answered	
in slide 18 left hand column? E.g., early	Live	
concept paper recommendations/feedback		and the state of t
Is there an estimated timeframe that FDA will		yes, basic feedback and a recommendation will be
communicate recommend/do not recommend		provided by December 15.
notices for the early Concept Paper submission?	Anguagaad	
There was one slide which mentioned a question about whether we had received an invitation to	Answered	
	Live	
submit a proposal in Oct-Nov 2024. I did not understand this comment in the context of the		
optional concept paper. Can applicants of one proposal be from two	Answered	
different organizations, such as two different	Live	
universities? In this case, through which entity to	LIVE	
submit the proposal?		
Can one investigator submit multiple concept	Answered	Multiple concept papers (for early optional
papers?	in Q&A Pod	concept paper) can be submitted, especially if
Labara.		the methodology and/or application is distinct.
		the methodology and/or application is distillet.

Question	Answer	Written Answer
Are the contracts cost sharing?		You can propose this.
Can the proposals that were not funded during		Yes.
the previous cycle be revised and submit as new		
or revised applications?		
From your experience, please provide some	Answered	
practical hints to prepare a good application.	Live	
What are critical points to focus on? What is the		
most common deficiency in the applications?		
What should be avoided, what to take care of		
particularly, etc. Thank you		
Have all the awards been made for the BAA for	Answered	
FY2023?	Live	
Are the deliverables intended for the public to	Answered	
use (e.g., statistical methods/designs) or they are	Live	
more intended for the agency?		
Considering the BAA FY24's emphasis on	Answered	
advanced manufacturing approaches, and based	Live	
on the feedback we received last year, can we		
resubmit a revised proposal that addresses the		
TEP's concerns by emphasizing our alignment		
with the BAA's objectives? Additionally, would		
it be appropriate to reference the feedback from last year in our updated proposal?		
Is there a reason I did not receive a response to	Answered	Please contact me (lan.Weiss@fda.hhs.gov)
my proposal from June? I was invited to round	in Q&A Pod	directly, as far as I am aware all notices were sent
two and I received positive feedback.	III QQA I Ou	out
What is the typical period of performance and a	Answered	
range of total contract value?	Live	
What is the typical period of performance and a	Answered	
range of total contract value?	Live	
What exactly is meant by remote monitoring?	Answered	
Is it to replace on-site inspections completely?	Live	
Or complement them?		
Can you send link to event?	Answered	https://www.fda.gov/science-research/2023-fda-
	in Q&A Pod	broad-agency-announcement-day-10252023
Who is a formal applicant in case of application	Answered	
from academia - a researcher or university?	Live	
After submitting an optional early concept paper,	Answered	
when can I expect to hear back from the on a	Live	
recommendation?		
What is your recommended way for getting	Answered	
in touch with you? Thank you.	Live	Descined to an acide a minute of the control of the
Is it mandatory to select a primary research area	Answered	Required to provide a primary research area but
and secondary research area for the concept	in Q&A Pod	NOT required for secondary research area. We
paper cover page?		want to make sure that the concept paper is
		evaluated by appropriate program leaders. Feel
		free to include more than one primary research
		area.

Question	Answer	Written Answer
What is the average project period? 2 - 3 years??		We have contracts ranging from 6 months to 5
		years. Most are 2-3 years.
When looking the SAM website, it asks about		You need to be registered for all awards in
NCAGE number for some applications. Would we		SAM.gov. Cage codes are being phased out.
need one?		
Who can apply? Small business? Academia	Answered	
(university)? Small business plus academic unit as	Live	
a joint applicant? Then, is a formal consortium of business & academic unit required?		
Can a firm submit more than one concept paper	Answered	For optional early concept paper, more than one
and/or proposal provided they are standalone	in Q&A Pod	concept paper per firm/institution can be
documents?		submitted for distinct applications and/or
		methodology. Any time after 11/6/2023, more
		than one concept paper with full proposal per
		firm/institution can be submitted for distinct
		applications and/or methodology.
Where can you find the chart that includes the	Answered	Chart is available as Table 1 of FY24 BAA
FDA-Regulated Areas and Demographics	in Q&A Pod	solicitation
Populations from the Concept Paper slides? - Kinnera		https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8
Please let us know if the reference list is within 3-	Answered	314343cb/view. The reference list is not part of the 3-page limit.
page limits?	in Q&A Pod	Please review Part III. Proposal Preparation and
page militor	πααπτοα	Submission of the BAA Announcement
For the Cross-Cutting section of the chart, how do	Answered	
we know which office or center within FDA we	Live	
should write to?		
As far as the size of the past awards, have the	Answered	
FY23 last cycle awards been posted to the BAA	Live	
site yet?	A	
Is the \$2M guidance for 1 year or over the course of multiple years (for example for a total of \$6M	Answered Live	
over 3 years)	Live	
Are we allowed to select more than one	Answered	only one charge area or regulatory topic area, but
regulatory area, topic area, or	in Q&A Pod	multiple product areas and
demographic/population for one proposal?		demographic/population can be posted. Please
		note that multiple primary and secondary research
		areas can be included.
Are there limits on direct and indirect costs?	Answered	
	Live	
The concept letter asks for high-level budget	Answered	
(with total). If submitted in November, how much	Live	
discretion do we have to modify for the final submission in February? thank you.		
Just to confirm- is it correct that if a vendor does	Answered	
not submit a concept paper by 11/6/23, they	Live	
exclude from submitting a full proposal by		
February 2024?		
reblualy 2024:		

Question	Answer	Written Answer
What do you mean performing 50% of the work?	Answered	
Sub vs prime.	Live	
When do you expect to make award decisions?		The May - June 2024 timeframe.
If our organization submitted an FY23 full		This is a business decision. However, you are
proposal and didn't hear back about an award		allowed to re-submit.
decision, should we resubmit under the FY24		
BAA, or should we wait to hear back under the		
FY23 BAA process? How can I attain feedback from my proposal last		Please contact us directly.
year? I was invited to stage two but never heard		Please contact us unectify.
back again		
Does business size (SB, LB) come into play when	Answered	
making award decisions? Is any of this set aside	Live	
for SBs?		
Could you please provide link for the FY23	Answered	https://sam.gov/opp/832533a9e79e4de2b4d06c1
results? The SAM page doesn't include the list of	in Q&A Pod	131f70722/view
awardees:		
https://sam.gov/opp/cee17d2a1ed84922a5a039		
2240a6f4e3/view Is there a different way to send questions? I can't	Answered	they can be sent to the BAA inbox, but only here
see questions that are presently been asked.	in Q&A Pod	live
can a system integrator outside organization	Answered	IIVC
be used	Live	
system integrator to provide management		This is a business decision. please keep the 51%
support		subcontracting rule in mind
Do we need to submit the optional	Answered	Send to FDABAA@FDA.HHS.GOV Please see table
concept paper through our university	in Q&A Pod	3 of FY24 BAA solicitation posting on
representative or just send directly through email? Thanks!		https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8
What's the minimum amount that you could	Answered	314343cb/view
award through BAA?	Live	
Are you less likely to receive funding if you	Answered	
recently received funding on a prior BAA?	Live	
Does the SAM registration have to be complete at	Answered	
the time of the early concept paper submission	Live	
or at the time of the full proposal?		
Would you recommend the non-primary	Answered	
applicants to also request a SAM number if they	Live	
don't have one? For example in the case of subcontracting. Thanks!		
Can the purchase of equipment be included (with	Answered	
a justification) in the cost?	Live	
please provide us the details for small business	Answered	https://sam.gov/opp/a9914d0313964d219e7c2ed
fair info. Thank you	in Q&A Pod	278daf743/view
can budget be broken up into options so that FDA		yes
can guide on what will be acceptable		

Question	Answer	Written Answer
Is it necessary to have proof of concept data for	Answered	
the proposed concept? Or is proof of principle	Live	
based on published data/basic preliminary data		
enough?		
In the previous year, the WHITE Paper is	Answered	Please review Dr. Kinnera Chada's presentation
considered as the Stage I proposal this year?	in Q&A Pod	and the FY24 BAA Announcement
Do ODCs purchased by Prime count towards	Answered	
51%?	Live	
I apologize, I did not hear an answer to this	Answered	On or about December 15th depending on the
question: After submitting an optional early	in Q&A Pod	shutdown
concept paper, when can I expect to hear back		
from the on a recommendation?		
Are references included in the 3 pages for	Answered	
concept paper	Live	
How do you find the most current chart listed in	Answered	
the instructions for the concept paper?	Live	
Can budget be submitted as options	Answered	
	Live	
Where can we find the codes and	Answered	See "Slide 12" of the presentation covered for the
explanation/definition of the FDA Primary	Live	topic "# Application Updates" on
Research Areas? Such as I.C.3.a. Secondary		https://www.fda.gov/science-research/2023-fda-
Research Area: I.F.4.b., Primary Research Area		broad-agency-announcement-day-
(i.e., II.B.7.e)		10252023#event-materials.
Where can we find the relevant	Answered	See "Slides 7-12" of the presentation covered
codes/description information for the	Live	for the topic "# Application Updates" on
following sections for the Concept Paper		https://www.fda.gov/science-research/2023-fda-
submission? • Charge Area:		broad-agency-announcement-day-
• Regulatory Science Topic Area of Interest:		10252023#event-materials.
• FDA Regulated Areas:		
Demographics and Populations:		
Primary Research Area:		
Secondary Research Area:		
We want to reconfirm about the concept paper	Answered	The 3 pages limit for the Concept Paper includes
page limit. Does the concept paper is limited to	Live	the Concept Paper Cover Page and Concept Paper
three (3) pages with single; Margins – 1 inch; Font		Overview. Page Size: 8 ½ x 11 inches; Spacing –
- Arial; Font Size - 12?		single; Margins – 1 inch; Font – Arial; Font Size –
		12. For details, see description for "Preparation of
		Concept Paper", Section 2: Stage 1 Concept Paper
		and Full Proposal Preparation of Concept Paper of Part III: Proposal Preparation and Submission of
		the solicitation on
		https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8
		314343cb/view.
		SITSTSCD/ VICW.

Question	Answer	Written Answer
Reconfirming - Within the limits of (3) three pages of the "Concept Paper" do we have to provide the below mentioned highlighted information? 1. Research Strategy: a. Aims: Succinctly list the specific objectives of the proposed research (State the problem/objective and provide motivation for addressing that problem/objective) and primary scientific challenges being addressed. b. Methods: Clearly describe the approach, description of level of effort, and the nature as well as extent of the anticipated results of the effort (one Figure that is a 508 compliant picture or graphic that illustrates the research or concept can be included) c. Considerations: Brief description of the Offerors intellectual property ownership, data ownership, or licensure; statements on work experience for similar effort with FDA or another agency 2. Regulatory Science Impact a. How does this research address an unmet need or fill a critical knowledge gap to advance regulatory science and the program's priorities? How might FDA apply the research findings to the development of new tools, approaches, or standards? Please explain the benefits of proposed technology and challenges and how the proposed project aligns with the objectives of FDA Regulatory Science 3. Proposed Deliverables and Funding a. List of the major goals, deliverables, or milestones and proposed funding by project year. Total proposed funding is the Base period cost plus each option period with no more than 5 years total.	Answered Live	The 3-page limit for the Concept Paper includes the Concept Paper Cover Page and Concept Paper Overview. The descriptive text (italicized red font) can be deleted or replaced. For details, see description for "Preparation of Concept Paper", Section 2: Stage 1 Concept Paper and Full Proposal Preparation of Concept Paper of Part III: Proposal Preparation and Submission of the solicitation on https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8 314343cb/view.
Milestones Timeline Funding on the Free-standing Concept Paper Submission.	Answered	See description for "Preparation of Concept
I'm interested in applying for the following FY24 FDA BAA for Advanced Research and Development of Regulatory Science opportunity, but could not find the format of the Free standing Optional Concept Paper from the following website. I could not find the attachment 4.	Live	Paper", Section 2: Stage 1 Concept Paper and Full Proposal Preparation of Concept Paper of Part III: Proposal Preparation and Submission of the solicitation. Attachment 4 is available in the solicitation and as a document on https://sam.gov/opp/26fa501e9b4d4f1ba8e1c2a8 314343cb/view.

Question	Answer	Written Answer
If we have several distinct ideas, would you	Answered	If the proposal applications and/or research
prefer we combine them into one 3-page	Live	methodology are distinct, the recommendation is
concept paper or submit them as separate proposals		to submit separate submissions.
proposais		
Does the three (3) page limit for the concept	Answered	The 3-page limit for the Concept Paper includes
paper (specified on page 70 of the <i>Broad Agency</i>	Live	the Concept Paper Cover Page and Concept Paper
Announcement) include the Concept Paper Cover Page? Table 3: Overview of BAA Application		Overview. Recommendations for Optional Early
Process on page 96 of the Broad Agency		Concept Paper submission will be communicated no later than December 15th (pending approval of
Announcement indicates that the FDA will notify		either a continuing resolution or appropriations of
submitters of the Optional Early Concept Paper of		funds for FDA).
the interest or lack of interest for full proposal		
submission. Does the FDA have a target date or		
date range in mind for sending these notifications		
out? 1. Will funding be available for Phase 1, 2 or 3	Answered	Broad Agency Announcements, as described in
clinical trials?	Live	the Federal Acquisition Regulations (FAR), may
2. Will the BAA fund the development of		only be issued for the procurement of Research
surrogate endpoints that could be used as the		and Development (R&D). All acquisitions resulting
basis for regulatory approval?		from this announcement must meet one or more
		of the FAR definitions for basic research (See FAR
		2.101(b)(2)), applied research (See FAR 35.001)
		and development (See FAR 35.001). Applications
		that describe how the project falls under the FAR
		requirements for R&D work will be considered for review.
3. Are there limitations on the size of the award?	Answered	
I notice that the response date on SAM.gov is	Live	All applications are due by February 19th, 2024
listed as February 14th, 2024 for the FY24		for FY24 funding considerations. SAM.gov will be
FDA BAA but all of the supporting documents		updated to reflect February 19, 2024.
and attachments list February 19, 2024. Can		, , , ,
you please clarify the date?		
We have a question about the Concept Paper		Yes, please remove the "descriptive text"
structure. Is it ok if we remove the descriptive		suggested for the concept paper
parts in red?		
1. Research Strategy:		
a. Aims: "Succinctly list the specific objectives of		
the proposed research (State the		
problem/objective and provide motivation for		
addressing that problem/objective) and primary		
scientific challenges being addressed" for the early concept paper submission due 11/6,		Yes, please include the budget in Concept Paper
do we need to include budget within that		Overview section for "Proposed Deliverables
submission?		and Funding". Provide proposed funding by
		project
		· · ·

Question	Answer	Written Answer
		year either as text or table provided in the
		template.